Production Method 1

99464-83-2

61622-34-2

95789-30-3

Reaction Conditions

1.1 Reagents: Sodium iodide Solvents: Acetonitrile ;  100 min, 50 °C
1.2 Reagents: Potassium carbonate Solvents: Acetone ,  Water ;  40 min, 28 °C
1.3 Solvents: Dichloromethane ;  20 min, -5 °C

Reference

Method for preparing and purifying cefotiam hexetil hydrochloride

, China, , ,

Production Method 2

99464-83-2

66309-69-1

95789-30-3

Reaction Conditions

1.1 Reagents: Sodium iodide ;  1.2 h; rt → 60 °C
1.2 Reagents: Triethylamine ;  15 min, reflux
1.3 Reagents: Hydrochloric acid ;  pH 1 - 2, 50 - 80 °C; 80 °C → -25 °C

Reference

One-pot method for preparing Cefotiam hexetil hydrochloride

, China, , ,

Production Method 3

95761-91-4

95789-30-3

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Water ;  1 - 5 °C; 1 h, 0 - 5 °C

Reference

Method for synthesis of low-solvent-residue Cefotiam hexetil hydrochloride

, China, , ,

Production Method 4

102672-57-1

95789-30-3

Reaction Conditions

1.1 Solvents: Dimethylformamide ;  0.5 h, -20 - -15 °C
1.2 Reagents: Sodium pyrosulfite Solvents: Ethyl acetate ,  Water ;  20 min
1.3 Reagents: Hydrochloric acid Solvents: Water ;  5 min, 0 °C

Reference

Method for preparation of Cefotiam hexetil hydrochloride with Cefotiam hydrochloride

, China, , ,

Production Method 5

102672-57-1

66309-69-1

95789-30-3

Reaction Conditions

1.1 Reagents: Sodium carbonate Solvents: Water ;  1 h, rt
1.2 Solvents: Dimethylformamide ;  12 min, 10 °C; cooled
1.3 Reagents: Hydrochloric acid Solvents: Acetone ,  Water ;  15 °C; 40 min, 15 °C; 25 min, 15 °C

Reference

Method for preparing Cefotiam hexetil hydrochloride from Cefotiam salt

, China, , ,

Production Method 6

102672-57-1

95789-30-3

Reaction Conditions

1.1 Solvents: Dimethylformamide ;  60 min, -15 - -10 °C
1.2 Reagents: Hydrochloric acid Solvents: Isopropanol ,  Ethyl acetate ;  -10 - -5 °C

Reference

Method for preparing Cefotiam hexetil

, China, , ,

Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) Raw materials

• 1-Chloroethyl Cyclohexyl Carbonate
• Cefotiam
• 1-Iodoethyl cyclohexylcarbonate
• Cefotiam hydrochloride
• 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]-8-oxo-,1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, (6R,7R)-

Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) Preparation Products

• Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) (95789-30-3)

• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactams Beta lactams Cephems

Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) and its Significance in Modern Pharmaceutical Research

Cas no95789-30-3 corresponds to the compound Cefotiam Hexetil Hydrochloride (mixture of Diastereomers), a significant entity in the realm of pharmaceutical chemistry. This compound, characterized by its unique diastereomeric mixture, has garnered considerable attention due to its potential applications in treating various infections. The diastereomers in this mixture contribute to its distinct pharmacological profile, making it a subject of extensive research and development.

The chemical structure of Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) is meticulously designed to enhance its efficacy and reduce the likelihood of resistance development. This is achieved through the strategic arrangement of functional groups that optimize its interaction with bacterial enzymes. The hydrochloride salt form enhances solubility, facilitating better absorption and distribution within the body, which is a critical factor in therapeutic success.

In recent years, there has been a growing interest in the development of novel antibiotics that can combat resistant bacterial strains. Cas no95789-30-3 represents a promising candidate in this endeavor. Studies have shown that the diastereomeric mixture exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria. This broad-spectrum activity is particularly valuable in clinical settings where infections may be caused by multiple types of bacteria.

The pharmacokinetic properties of Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) have been extensively evaluated to ensure optimal therapeutic outcomes. Research indicates that the compound exhibits a favorable half-life, allowing for less frequent dosing while maintaining effective blood levels. This aspect is crucial for patient compliance and overall treatment efficacy. Additionally, the compound's low toxicity profile makes it suitable for long-term use, which is essential for managing chronic infections.

One of the most compelling aspects of Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) is its mechanism of action. Unlike traditional antibiotics that target bacterial cell wall synthesis, this compound inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This targeted approach not only enhances its effectiveness but also reduces the impact on host cells, thereby minimizing side effects. The unique interaction with bacterial ribosomes also contributes to its resistance profile, making it less susceptible to bacterial resistance mechanisms.

Recent clinical trials have demonstrated the efficacy of Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) in treating a variety of infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). These findings are particularly significant given the increasing prevalence of multidrug-resistant bacteria worldwide. The ability to address these challenging infections underscores the importance of compounds like Cas no95789-30-3 in modern medicine.

The development of Cefotiam Hexetil Hydrochloride (mixture of Diastereomers) also highlights advancements in synthetic chemistry and drug design. The ability to create a stable mixture of diastereomers has opened new avenues for optimizing drug properties without compromising efficacy. This approach aligns with the broader goal of developing more sophisticated and effective pharmaceutical agents.

The future prospects for Cas no95789-30-3 are promising, with ongoing research aimed at further refining its pharmacological properties and exploring new therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are expected to yield innovative formulations and combination therapies that could enhance its clinical utility.

In conclusion, Cefotiam Hexetil Hydrochloride (mixture of Diastereomers), identified by Cas no95789-30-3, represents a significant advancement in antibiotic development. Its unique diastereomeric structure, favorable pharmacokinetic properties, and broad-spectrum activity make it a valuable asset in the fight against bacterial infections. As research continues to uncover new applications and improve formulations, this compound is poised to play a crucial role in addressing global health challenges related to antimicrobial resistance.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)